

Cell and Gene Therapy (CGT) Access Model Notice of Funding Opportunity (NOFO) Factsheet

CGT ACCESS MODEL NOFO PURPOSE

The CGT Access Model will test whether a CMS-led approach to developing and administering outcomes-based agreements (OBAs) for cell and gene therapies (CGTs) improves Medicaid beneficiaries' health outcomes, broadens access to innovative treatment, and reduces health care expenditures.



The Notice of Funding Opportunity (NOFO) announces the opportunity to apply for **Cooperative Agreement funding** to support states' participation in the CGT Access Model.

The [CGT Access Model NOFO](#) is open to all states, the District of Columbia, and all U.S. territories participating in the Medicaid Drug Rebate Program (MDRP).

NOFO DETAILS



FUNDING AMOUNT

up to **\$9.55M**

for each state, over the duration of the model

Total funding available to all recipients through the Cooperative Agreement is \$95.5M.

Cooperative Agreement funding is intended to support state model implementation activities and to support states that take steps to improve equitable access to gene therapy and promote multi-disciplinary, comprehensive care in conjunction with the model test.



Cooperative Agreements differ from grants in that they involve substantial interaction between the federal awarding agency and the non-federal entity carrying out activities under the award. However, many of the same statutes, regulations, and policies that apply to grants also apply to cooperative agreements.

FUNDING STRUCTURE

Two types of funding will be available under the Cooperative Agreement:



Implementation Funding

for model activities that involve staff/contractor time and infrastructure costs



Milestone Funding

for successful completion of research projects

NOFO APPLICATION PROCESS AND TIMELINE

CMS requires electronic submission of applications on [grants.gov](https://www.grants.gov) by February 28, 2025, 11:59 pm EST. The anticipated award date will be July 1, 2025.

To be considered, an applicant must apply to both the CGT Access Model [State Request for Applications \(RFA\)](#) and the [NOFO](#). Both applications are due by February 28, 2025.

Cell and Gene Therapy (CGT) Access Model Notice of Funding Opportunity (NOFO) Factsheet

IMPLEMENTATION FUNDING



Implementation Funding will support required and optional model activities that involve staff/contractor time and infrastructure costs. Applicants may request Implementation Funding for:

Necessary activities to implement model requirements (see [State RFA](#))



Development of new state statutory authorities or State Plan Amendments



Expansion of staff capacity/personnel or contractor support



Outreach to and engagement with interested parties



Coordination with managed care plans and gene therapy providers

Optional activities to increase equitable access to gene therapy or promote comprehensive care



Awareness, education, and access to specialty care



Behavioral health services



Health-related social needs



Care coordination



Family planning

PARTNERSHIPS

States can use Implementation Funding to partner with community-based organizations (CBOs) with a focus on providing services to individuals with sickle cell disease (SCD). Implementation Funding can be used to pay CBOs for the following purposes:

Increasing awareness and education of gene therapy

Increasing awareness and access to supportive ancillary services

Providing services to address health-related social needs

Providing community health worker/patient navigator and peer supports

REPORTING REQUIREMENTS

Recipients will be required to comply with federal reporting requirements and submit model-specific progress reports.



For **required model activities**, states must comply with State RFA reporting requirements.



For **optional model activities**, states must propose reporting milestones and an implementation plan for CMS approval and must submit progress reports.



For **partnerships with CBOs**, states must also submit CBO performance reports and partnership lists.

Cell and Gene Therapy (CGT) Access Model Notice of Funding Opportunity (NOFO) Factsheet

MILESTONE FUNDING



Milestone Funding will support successful completion of research projects related to increasing equitable access to SCD gene therapy and promoting multi-disciplinary, comprehensive care for beneficiaries with SCD who are considering or receiving SCD gene therapy.

To receive Milestone Funding, projects must:



Be related to the [patient care journey](#) for SCD gene therapy.



Include primary data collection from model beneficiaries, caregivers, providers, and/or CBOs.



The current state of patient care, barriers, and potential opportunities for improvement.



The effect of a policy change or intervention.

To receive Milestone Funding for a project, the state must submit a report describing their study, research findings, and lessons learned.

PARTNERSHIPS

States can partner with organizations to conduct Milestone Funding research projects. Partner organizations may include:



Community-based organizations



Treatment centers qualified to administer gene therapy for SCD



Academic institutions

REPORTING REQUIREMENTS

If a state seeks Milestone Funding for performance on a project, it must verify its progress through quarterly and annual reporting.



The state must submit a full performance report to CMS demonstrating completion of the project from the prior performance year.

Milestone Funding is not guaranteed and will be restricted (unavailable) unless CMS approves the state's performance report and verifies that the state has successfully completed the project.

Model Contact Information and Resources

[CGT Access Model Listserv](#)
[CGT Access Model Overview Factsheet](#)
[CGT Access Model Website](#)
[CGT Access Model State RFA Factsheet](#)

[NOFO Application](#)
[NOFO Frequently Asked Questions](#)

Email: CGTModel@cms.hhs.gov